References:
- Tabrizi AD, Melli MS, Foroughi M, et al. Antiproliferative effect of metformin on the endometrium: a clinical trial. Asian Pac J Cancer Prev 2014;15:10067–70
- Kashanian M, Fazy Z, Pirak A. Evaluation of the relationship between gestational diabetes and a history of polycystic ovarian syndrome. Diabetes Res Clin Pract 2008;80:289–92
- Session DR, Kalli KR, Tummon IS, et al. Treatment of atypical endometrial hyperplasia with an insulin-sensitizing agent. Gynecol Endocrinol 2003;17:405–7
- Javanmanesh F, Kashanian M, Rahimi M, Sheikhansari N. A comparison between the effects of metformin and N-acetyl cysteine (NAC) on some metabolic and endocrine characteristics of women with polycystic ovary syndrome. Gynecol Endocrinol 2016;32:285–9
- Beck E, Scheen AJ. Anti-cancer activity of metformin: new perspectives for an old drug. Rev Med Suisse 2010;6:1601–7
- Papanas N, Maltezos E, Mikhailidis DP. Metformin and cancer: licence to heal? Expert Opin Investig Drugs 2010;19:913–17
- Bost F, Sahra IB, Le Marchand-Brustel Y, Tanti JF. Metformin and cancer therapy. Curr Opin Oncol 2012;24:103–8
- Ben Sahra I, Le Marchand-Brustel Y, Tanti JF, Bost F. Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol Cancer Ther 2010;9:1092–9
- Micic D, Cvijovic G, Trajkovic V, et al. Metformin: its emerging role in oncology. Hormones (Athens) 2011;10:5–15
- Li B, Takeda T, Tsuiji K, et al. The antidiabetic drug metformin inhibits uterine leiomyoma cell proliferation via an AMP-activated protein kinase signaling pathway. Gynecol Endocrinol 2013;29:87–90
- Cantrell LA, Zhou C, Mendivil A, et al. Metformin is a potent inhibitor of endometrial cancer cell proliferation–implications for a novel treatment strategy. Gynecol Oncol 2010;116:92–8
- Kacalska O, Krzyczkowska-Sendrakowska M, Milewicz T, et al. Molecular action of insulin-sensitizing agents. Endokrynol Pol 2005;56:308–13
- Li X, Guo YR, Lin JF, et al. Combination of Diane-35 and metformin to treat early endometrial carcinoma in PCOS women with insulin resistance. J Cancer 2014;5:173–81
- Tas M, Kutuk MS, Serin IS, et al. Comparison of antiproliferative effects of metformine and progesterone on estrogen-induced endometrial hyperplasia in rats. Gynecol Endocrinol 2013;29:311–14
- Shen ZQ, Zhu HT, Lin JF. Reverse of progestin-resistant atypical endometrial hyperplasia by metformin and oral contraceptives. Obstet Gynecol 2008;112:465–7
- Sivalingam VN, Kitson S, McVey R, et al. Measuring the biological effect of presurgical metformin treatment in endometrial cancer. Br J Cancer 2016;114:281–9
- Mitsuhashi A, Sato Y, Kiyokawa T, et al. Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer. Ann Oncol 2016;27:262–6
- Shan W, Wang C, Zhang Z, et al. Conservative therapy with metformin plus megestrol acetate for endometrial atypical hyperplasia. J Gynecol Oncol 2014;25:214–20
- Campagnoli C, Abbà C, Ambroggio S, et al. Life-style and metformin for the prevention of endometrial pathology in postmenopausal women. Gynecol Endocrinol 2013;29:119–24